Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2018

View Archived Issues

ANI Pharmaceuticals acquires NDAs, U.S. rights to four AstraZeneca products

CStone Pharmaceuticals announces IND filing in Australia

FDA clears Ignyta's IND for RXDX-106 study

Wanbang Biopharmaceuticals submits IND in China for SGLT2 inhibitor

FDA accepts Progenics' Azedra NDA for review

Siglec-7 targeting shows promise against multiple myeloma

Galapagos and Servier report ADAMTS inhibitors for osteoarthritis

CXCL12 shown to impact tipifarnib benefit in AML and MDS patients

Oncimmune signs framework agreement with Genostics for EarlyCDT platform in China

Vitae Pharmaceuticals patents Menin/MLL interaction inhibitors

GABA(A) receptor agonists reported in Sichuan Haisco Pharmaceutical patent

Phase III study of EG-1962 in aneurysmal subarachnoid hemorrhage recommended to continue

Universita del Piemonte Orientale prepares and tests CRAC modulators

GlaxoSmithKline patents describe ATF4 inhibitors

Atara cleared to begin phase III studies of tabelecleucel

Servier and Vernalis jointly patent USP7 inhibitors

ImmunoPrecise Antibodies invests in SERPINx to develop serine protease inhibitors

SELLAS Life Sciences Group completes merger with Galena Biopharma

Bio-Path updates pipeline progress

Global Foundation for Human Aging Research funds research at Dana-Farber into cellular aging

PHF2 expression impacts survival of ALL patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...